Factors Influencing a Specific Pathologic Diagnosis of Non-Small-Cell Lung Carcinoma

被引:6
|
作者
Sulpher, Jeffrey A. [1 ]
Owen, Scott P. [2 ]
Hon, Henrique [2 ]
Tobros, Kimberly [2 ]
Shepherd, Frances A. [2 ]
Sabri, Elham [3 ]
Gomes, Marcio [4 ]
Sekhon, Harman [4 ]
Liu, Geoffrey [2 ]
Canil, Christina M. [1 ]
Wheatley-Price, Paul [1 ]
机构
[1] Univ Ottawa, Dept Med, Ottawa Hosp, Ctr Canc, Ottawa, ON, Canada
[2] Univ Toronto, Univ Hlth Network, Princess Margaret Hosp, Div Med Oncol & Hematol,Dept Med, Toronto, ON M5S 1A1, Canada
[3] Univ Ottawa, Res Inst, Ottawa Hosp, Ottawa, ON, Canada
[4] Univ Ottawa, Dept Pathol & Lab Med, Ottawa Hosp, Ottawa, ON, Canada
关键词
Chart review; Diagnosis; Histology; Non-small-cell lung cancer; CANCER; CHEMOTHERAPY; MUTATIONS; GEFITINIB; CYTOLOGY; EGFR; ADENOCARCINOMA; CLASSIFICATION; CARBOPLATIN; PACLITAXEL;
D O I
10.1016/j.cllc.2012.11.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pathologic subtyping of non-small-cell lung carcinoma is increasingly important when selecting therapy. The records of 739 patients were reviewed to identify factors associated with attaining a specific pathologic diagnosis. Only 456 (62%) of patients received a specific pathologic diagnosis, which was significantly associated with histologic biopsy samples, immunohistochemical testing, and diagnosis outside of an academic center. Introduction: Historically, a non-small-cell lung carcinoma diagnosis, without pathologic subclassification, provided sufficient information to guide therapy. Evidence now demonstrates that pathologic subtype classification is central in selecting optimal treatment. This review aimed to identify factors associated with a specific pathologic diagnosis. Methods: All nonoperative cases of non-small-cell lung carcinoma (NSCLC) referred to the medical oncology divisions of the Ottawa Hospital Cancer Centre (2008) and Princess Margaret Hospital, Toronto (2007-2010) were identified. The charts were reviewed for demographics, diagnostic methods, and final diagnosis. Logistic regression was performed to identify variables associated with a specific diagnosis. Results: Of 739 patient records analyzed, 377 (51%) were men, 299 (40%) were aged over 70 years, and 510 (69%) had an Eastern Cooperative Oncology Group performance status of 0-2. Three hundred and eighty five (52%) of patients were diagnosed in a tertiary academic center. The lung primary was sampled in 503 (68%) of patients. Computed tomography-guided biopsy (n = 370, 50%) and bronchoscopy (n = 179, 24%) were the most common techniques. Four hundred and seventy seven (65%) of biopsies were cytologic specimens alone, and immunohistochemistry was performed in 337 (46%) of cases. The most common diagnoses were adenocarcinoma (n = 338, 46%), NSCLC not otherwise specified (n = 254, 34%), and squamous cell carcinoma (n = 115, 16%). Overall, 456 (62%) of patients received a specific pathologic diagnosis. Factors significantly associated with attaining a specific pathologic diagnosis were diagnosis outside an academic center (adjusted odds ratios [OR] 2.1 [95% CI, 1.41-3.14]; P = .0003), histologic laboratory samples (adjusted OR 1.58 [95% CI, 1.003-2.49]; P = .049), and immunohistochemical testing (adjusted OR 1.82 [95% CI, 1.25-2.70], P = .0021). Conclusions: A significant minority of patients with NSCLC do not receive a specific pathologic diagnosis. In an era of individualized medicine, this may potentially impact optimal clinical management. Clinical Lung Cancer, Vol. 14, No. 3, 238-44 (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:238 / 244
页数:7
相关论文
共 50 条
  • [1] Radiotherapy and targeted therapies in non-small-cell lung cancer
    Girard, N.
    Mornex, F.
    BULLETIN DU CANCER, 2009, 96 (03) : 311 - 319
  • [2] Crizotinib in the treatment of non-small-cell lung carcinoma
    Pluzanski, Adam
    Piorek, Aleksandra
    Krzakowski, Maciej
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2012, 16 (06): : 480 - 484
  • [3] Detection of epidermal growth factor receptor mutation in non-small-cell lung carcinoma using cytological and histological specimens
    Xu, Haimiao
    Sun, Wenyong
    Zhang, Gu
    Cheng, Yue
    JOURNAL OF BUON, 2015, 20 (01): : 142 - 145
  • [4] Non-Small-Cell Lung Carcinoma Subtyping on Cytology without the Use of Immunohistochemistry - Can We Meet the Challenge?
    Manucha, Varsha
    Wang, Congli
    Huang, Yajue
    ACTA CYTOLOGICA, 2012, 56 (04) : 413 - 418
  • [5] EGFR mutation analysis in non-small-cell lung cancer
    Tapia, C.
    Savic, S.
    Bihl, M.
    Rufle, A.
    Zlobec, I.
    Terracciano, L.
    Bubendorf, L.
    PATHOLOGE, 2009, 30 (05): : 384 - 392
  • [6] EGFR mutation analysis in non-small-cell lung cancer
    Tapia, C.
    Savic, S.
    Bihl, M.
    Rufle, A.
    Zlobec, I.
    Terracciano, L.
    Bubendorf, L.
    PATHOLOGE, 2009, 30 (05): : 384 - 392
  • [7] Differential expression of Yes-associated protein is correlated with expression of cell cycle markers and pathologic TNM staging in non-small-cell lung carcinoma
    Kim, Jin Man
    Kang, Dong Wook
    Long, Liang Zhe
    Huang, Song-Mei
    Yeo, Min-Kyung
    Yi, Eunhee S.
    Kim, Kyung-Hee
    HUMAN PATHOLOGY, 2011, 42 (03) : 315 - 323
  • [8] Molecular targeted therapy of patients with non-small-cell lung cancer
    Stencel, Katarzyna
    Swiniuch, Daria
    Ramlau, Rodryg
    ONCOLOGY IN CLINICAL PRACTICE, 2019, 15 (06): : 289 - 296
  • [9] RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis
    Tsuta, K.
    Kohno, T.
    Yoshida, A.
    Shimada, Y.
    Asamura, H.
    Furuta, K.
    Kushima, R.
    BRITISH JOURNAL OF CANCER, 2014, 110 (06) : 1571 - 1578
  • [10] Maintenance chemotherapy for non-small-cell lung cancer
    Kim, Young Hak
    Mishima, Michiaki
    CANCER TREATMENT REVIEWS, 2011, 37 (07) : 505 - 510